# COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer

> **NCT07328087** · EARLY_PHASE1 · RECRUITING · sponsor: **Biogenea Pharmaceuticals Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic
- Colorectal Cancer Stage III
- Colorectal Cancer Stage IV

## Interventions

- **BIOLOGICAL:** Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab

## Key facts

- **NCT ID:** NCT07328087
- **Lead sponsor:** Biogenea Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2030-12-02
- **Final completion:** 2031-12-02
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07328087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07328087, "COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07328087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*